Biotechnology Trxade Health (MEDS) reports 20% growth in Q4 revenue; results beat estimates 3 years ago Trxade Health Inc (NASDAQ: MEDS) Monday reported a narrower net loss for the fourth quarter of 2021 as the pharmaceutical services… Catalyst Pharmaceuticals Inc. (CPRX) Q4 2021 Earnings Call Transcript 3 years ago Catalyst Pharmaceuticals Inc. (NASDAQ: CPRX) Q4 2021 earnings call dated Mar. 17, 2022 Corporate Participants: Alicia Grande -- Vice President, Chief Financial… AN2 Therapeutics takes IPO route to advance pipeline. Here’s all you need to know 3 years ago After starting the year on a high note, the IPO market is currently going through a slow phase mainly due… Bio-Path Holdings, Inc. (BPTH) Q4 2021 Earnings Call Transcript 3 years ago Bio-Path Holdings, Inc. (NASDAQ: BPTH) Q4 2021 earnings call dated Mar. 11, 2022 Corporate Participants: Will O'Connor -- Investor Relations Peter Nielsen -- President,… Avid Bioservices, Inc. (CDMO) Q3 2022 Earnings Call Transcript 3 years ago Avid Bioservices, Inc. (NASDAQ: CDMO) Q3 2022 earnings call dated Mar. 08, 2022 Corporate Participants: Tim Brons -- Investor Relations Nicholas Green -- President… Novavax, Inc. (NVAX) Q4 2021 Earnings Call Transcript 3 years ago Novavax, Inc. (NASDAQ: NVAX) Q4 2021 earnings call dated Feb. 28, 2022 Corporate Participants: Silvia Taylor -- Senior Vice President of Global… FibroGen, Inc. (FGEN) Q4 2021 Earnings Call Transcript 3 years ago FibroGen, Inc. (NASDAQ: FGEN) Q4 2021 earnings call dated Feb. 28, 2022 Corporate Participants: Michael Tung -- Vice President, Corporate Strategy &… ImmunoGen, Inc. (IMGN) FY 2021 Earnings Call Transcript 3 years ago ImmunoGen, Inc. (NASDAQ: IMGN) FY 2021 earnings call dated Feb. 25, 2022 Corporate Participants: Courtney O'Konek -- Senior Director of Corporate Communications… Moderna, Inc. (MRNA) Q4 2021 Earnings Call Transcript 3 years ago Moderna, Inc. (NASDAQ: MRNA) Q4 2021 earnings call dated Feb. 24, 2022 Corporate Participants: Lavina Talukdar -- Senior Vice President & Head of… Sage Therapeutics, Inc. (SAGE) Q4 2021 Earnings Call Transcript 3 years ago Sage Therapeutics, Inc. (NASDAQ: SAGE) Q4 2021 earnings call dated Feb. 24, 2022 Corporate Participants: Helen Rubinstein -- Investor Relations Officer Barry… Corcept Therapeutics Incorporated (CORT) Q4 2021 Earnings Call Transcript 3 years ago Corcept Therapeutics Incorporated (NASDAQ: CORT) Q4 2021 earnings call dated Feb. 15, 2022 Corporate Participants: Atabak Mokari -- Chief Financial Officer Charles… Ocean Biomedical slashes IPO size. Should you invest in the stock? 3 years ago The biomedical industry grew at an accelerated pace in 2021 even as healthcare systems went into overdrive amidst the COVID-induced… Regeneron Pharmaceuticals Inc. (REGN) Q4 2021 Earnings Call Transcript 3 years ago Regeneron Pharmaceuticals Inc. (NASDAQ: REGN) Q4 2021 earnings call dated Feb. 04, 2022 Corporate Participants: Mark Hudson -- Director, Investor Relations Leonard… Infographic: A snapshot of Merck’s Q4 2021 earnings 3 years ago Pharmaceuticals company Merck & Co., Inc. (NYSE: MRK) has reported stronger-than expected earnings and revenues for the fourth quarter. The… BIIB Earnings: Key quarterly highlights from Biogen’s Q4 2021 financial results 3 years ago Biogen Inc. (NASDAQ: BIIB) reported fourth quarter 2021 earnings results today. Total revenue decreased 4% year-over-year to $2.73 billion. GAAP… Arcellx readies for $140-mln IPO. Here’s all you need to know 3 years ago The IPO market is recovering from the slowdown experienced towards the end of 2021, with pharma companies dominating the scene… Vertex Pharmaceuticals Incorporated (VRTX) Q4 2021 Earnings Call Transcript 3 years ago Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) Q4 2021 earnings call dated Jan. 26, 2022 Corporate Participants: Michael Partridge -- Senior Vice President of… INTERVIEW: Evelo’s SINTAX medicines could address a broad range of inflammatory disorders 3 years ago Credit:DavidBGray on iStock Evelo Biosciences (Nasdaq:EVLO) is a clinical-stage biotechnology company that is focused on a newly uncovered area of… Bristol-Myers bets on product pipeline to beat patent issues. Is BMY a buy? 3 years ago The pharma sector has been on a stable growth trajectory lately, and the trend gathered momentum when the pandemic-related emergency… Addex Therapeutics CEO Tim Dyer: There is a $4-bil market opportunity in dyskinesia 3 years ago Credit:DavidBGray on iStock Tell us a bit about your clinical programs and how they are different from the existing therapies.… Equillium CEO Bruce Steel: We are among the few evaluated in first-line GVHD treatment 3 years ago Credit:DavidBGray on iStock What is Equillium all about? We started the company four years ago around our lead drug program… Next» « Previous